Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Entinostat (Primary) ; Exemestane
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Kyowa Hakko Kirin
- 03 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Oct 2017 According to a Syndax Pharmaceuticals media release, first patient has been dosed.
- 28 Sep 2017 New source identified and integrated(ClinicalTrials.gov NCT03291886)